Phe-Lys(Trt)-PAB
CAS No. 1116085-99-4
Phe-Lys(Trt)-PAB ( —— )
Catalog No. M27000 CAS No. 1116085-99-4
Phe-Lys(Trt)-PAB is a cathepsin cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 120 | Get Quote |
|
10MG | 170 | Get Quote |
|
25MG | 308 | Get Quote |
|
50MG | 439 | Get Quote |
|
100MG | 627 | Get Quote |
|
200MG | 897 | Get Quote |
|
500MG | 1332 | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePhe-Lys(Trt)-PAB
-
NoteResearch use only, not for human use.
-
Brief DescriptionPhe-Lys(Trt)-PAB is a cathepsin cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
-
DescriptionPhe-Lys(Trt)-PAB is a cathepsin cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).(In Vitro):ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1116085-99-4
-
Formula Weight640.8
-
Molecular FormulaC41H44N4O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN[C@@H](Cc1ccccc1)C(=O)N([C@@H](CCCCNC(c1ccccc1)(c1ccccc1)c1ccccc1)C(N)=O)c1ccc(CO)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.de Veth MJ, et al. Choline absorption and evaluation of bioavailability markers when supplementing choline to lactating dairy cows. J Dairy Sci. 2016 Dec;99(12):9732-9744.
molnova catalog
related products
-
Lanreotide acetate
Lanreotide acetate is a somatostatin analogue with antineoplastic activity used for carcinoid syndrome.
-
JAK2 Inhibitor V
NSC 42834(JAK2 Inhibitor V, Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.
-
FFAGLDD TFA
FFAGLDD TFA is an MMP9 selective cleavage peptide, which is used for the cytoplasmic transfer of doxorubicin (DOX) to realize the controlled slow drug delivery and release.